David Moskowitz on 8VC's Investment in Model Medicines
David Moskowitz sits down with Daniel Haders II, Ph.D. in Episode 3 of our four-part series to talk about why 8VC invested in Model Medicines, and how their approach to drug discovery and development – one built on fundamental chemistry – fits within 8VC's overall Bio-IT investment portfolio. The two will dive deep into the company’s vision; highlight recent partnerships; and the successes they’ve had along the way.
In Today’s Episode You Will Learn
8VC seeks to partner with top founders and entrepreneurs to build lasting technology platforms and create long-term economic and societal value. How does David envision Model Medicines, a cheminformatics based AI drug discovery company, fitting within 8VC’s existing Bio-IT portfolio?
We are in a period where data and software can't do everything on its own, but by partnering with the great labs of the world Model Medicines is able to do something that wasn't previously possible on time scales that can create products that can impact your human life and human health in days rather than decades. Why does David believe the “man-machine symbiosis” approach has led Model Medicines to partner with some of the world leading labs and researchers, like their most recent partnership with Sumit Chanda, PhD’s of Sanford Burnham Presby.
David Moskowitz focuses on the Bio-IT space. Prior to joining 8VC, David completed his Ph.D. in Biomedical Informatics at Stanford University, where he concurrently received an M.S. in Statistics. His research focused on the development of statistical and machine learning approaches for analyzing genomics data, and the characterization of epigenetic changes associated with aging in T cells. Previously, David was a Bioinformatic Analyst at Einstein College of Medicine, where he worked on the genetics of aging and human disease. He performed his undergraduate studies in Computational Biology at Brown University.
